title: Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones.
abstract: Vascular endothelial growth factor (VEGF) and beta-catenin both act broadly in embryogenesis and adulthood, including in the skeletal and vascular systems. Increased or deregulated activity of these molecules has been linked to cancer and bone-related pathologies. By using novel mouse models to locally increase VEGF levels in the skeleton, we found that embryonic VEGF over-expression in osteo-chondroprogenitors and their progeny largely pheno-copied constitutive beta-catenin activation. Adult induction of VEGF in these cell populations dramatically increased bone mass, associated with aberrant vascularization, bone marrow fibrosis and haematological anomalies. Genetic and pharmacological interventions showed that VEGF increased bone mass through a VEGF receptor 2- and phosphatidyl inositol 3-kinase-mediated pathway inducing beta-catenin transcriptional activity in endothelial and osteoblastic cells, likely through modulation of glycogen synthase kinase 3-beta phosphorylation. These insights into the actions of VEGF in the bone and marrow environment underscore its power as pleiotropic bone anabolic agent but also warn for caution in its therapeutic use. Moreover, the finding that VEGF can modulate beta-catenin activity may have widespread physiological and clinical ramifications.
authors.affiliation: Laboratory of Experimental Medicine and Endocrinology, Department of Experimental Medicine, KU Leuven, Leuven, Belgium.
authors.forename: Christa
authors.initials: C
authors.lastname: Maes
authors.forename: Steven
authors.initials: S
authors.lastname: Goossens
authors.forename: Sonia
authors.initials: S
authors.lastname: Bartunkova
authors.forename: Benjamin
authors.initials: B
authors.lastname: Drogat
authors.forename: Lieve
authors.initials: L
authors.lastname: Coenegrachts
authors.forename: Ingrid
authors.initials: I
authors.lastname: Stockmans
authors.forename: Karen
authors.initials: K
authors.lastname: Moermans
authors.forename: Omar
authors.initials: O
authors.lastname: Nyabi
authors.forename: Katharina
authors.initials: K
authors.lastname: Haigh
authors.forename: Michael
authors.initials: M
authors.lastname: Naessens
authors.forename: Lieven
authors.initials: L
authors.lastname: Haenebalcke
authors.forename: Jan P
authors.initials: JP
authors.lastname: Tuckermann
authors.forename: Marc
authors.initials: M
authors.lastname: Tjwa
authors.forename: Peter
authors.initials: P
authors.lastname: Carmeliet
authors.forename: Vice
authors.initials: V
authors.lastname: Mandic
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: David
authors.forename: Axel
authors.initials: A
authors.lastname: Behrens
authors.forename: Andras
authors.initials: A
authors.lastname: Nagy
authors.forename: Geert
authors.initials: G
authors.lastname: Carmeliet
authors.forename: Jody J
authors.initials: JJ
authors.lastname: Haigh
mesh_terms: D000818:Animals; D001842:Bone and Bones / Q000196:embryology / Q000378:metabolism* / Q000473:pathology*; D002454:Cell Differentiation; D049109:Cell Proliferation; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000166:cytology; D018507:Gene Expression Regulation, Developmental; D006801:Humans; D008648:Mesoderm / Q000166:cytology; D051379:Mice; D008822:Mice, Transgenic; D009024:Morphogenesis; D010006:Osteoblasts / Q000166:cytology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D013234:Stem Cells / Q000166:cytology; D017154:Stromal Cells / Q000166:cytology; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism*
chemical_list: D042461:Vascular Endothelial Growth Factor A; D051176:beta Catenin; D019869:Phosphatidylinositol 3-Kinases